Cargando…

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea

BACKGROUND: Vortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a large post-marketing surveillance study in So...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cumbo, Eduardo, Adair, Michael, Åstrom, Daniel Oudin, Christensen, Michael Cronquist
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Aging Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868833/ https://www.ncbi.nlm.nih.gov/pubmed/36698860 http://dx.doi.org/10.3389/fnagi.2022.1037816

Ejemplares similares

Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study
por: Almeida, Susana S, et al.
Publicado: (2022)

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre, Roger S, et al.
Publicado: (2021)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
por: Polosan, Mircea, et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
por: De Filippis, Sergio, et al.
Publicado: (2022)

A Systematic Analysis on the Genes and Their Interaction Underlying the Comorbidity of Alzheimer's Disease and Major Depressive Disorder
por: Guo, Pan, et al.
Publicado: (2022)

Alzheimer’s disease and epilepsy: An increasingly recognized comorbidity
por: Yang, Fei, et al.
Publicado: (2022)

Highlighting the value of Alzheimer’s disease-focused registries: lessons learned from cancer surveillance
por: Miller, Margaret C., et al.
Publicado: (2023)

Assessing Reliability and Validity of the Oxford Depression Questionnaire (ODQ) in a Japanese Clinical Population
por: Kato, Masaki, et al.
Publicado: (2023)

Loop diuretics association with Alzheimer’s disease risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

The effect of physical activity on white matter integrity in aging and prodromal to mild Alzheimer’s disease with vascular comorbidity
por: Konwar, Srijan, et al.
Publicado: (2023)

Intradialytic resistance training for short daily hemodialysis patients as part of the clinical routine: a quasi-experimental study
por: Baião, Victor M., et al.
Publicado: (2023)

Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients
por: Farheen, Saba, et al.
Publicado: (2021)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
por: Moon, Seok Woo, et al.
Publicado: (2023)

G-quadruplexes and associated proteins in aging and Alzheimer’s disease
por: Vijay Kumar, M. J., et al.
Publicado: (2023)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Editorial: Molecular mechanisms of Alzheimer’s disease: From top to bottom
por: Mello-Carpes, Pâmela B., et al.
Publicado: (2022)

Neuropathology of Aging in Cats and its Similarities to Human Alzheimer’s Disease
por: Sordo, Lorena, et al.
Publicado: (2021)

Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer’s Disease
por: Cox, MaKayla F., et al.
Publicado: (2022)

Amyloid-β in Alzheimer’s disease – front and centre after all?
por: Weglinski, Caroline, et al.
Publicado: (2023)

Correlation analysis of monocyte chemoattractant protein-1 and clinical characteristics and cognitive impairment in type 2 diabetes mellitus comorbid major depressive disorder
por: Cao, Fang, et al.
Publicado: (2023)

PS83. Impact of Vortioxetine on Functional Capacity in MDD Patients with Subjective Cognitive Dysfunction: A Post-hoc Analysis of the University of California San Diego Performance-Based Skills Assessment
por: Jacobson, William, et al.
Publicado: (2016)

The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
por: Hunsberger, Holly C., et al.
Publicado: (2019)

Sex Differences in Large Artery Stiffness: Implications for Cerebrovascular Dysfunction and Alzheimer’s Disease
por: Kehmeier, Mackenzie N., et al.
Publicado: (2021)

Iron chelators as a therapeutic option for Alzheimer’s disease—A mini-review
por: Schreiner, Oliver Daniel, et al.
Publicado: (2023)

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
por: Yu, Weiwei, et al.
Publicado: (2021)

Impact of alcohol-induced intestinal microbiota dysbiosis in a rodent model of Alzheimer’s disease
por: Frausto, Dulce M., et al.
Publicado: (2022)

Somatic comorbidity and the progression of cognitive impairment
por: Bidzan, Leszek, et al.
Publicado: (2023)

Effect of vortioxetine on proinflammatory cytokine levels in patients with heart failure and comorbid depression
por: Sikora, A., et al.
Publicado: (2021)

Effects of DISC1 on Alzheimer’s disease cell models assessed by iTRAQ proteomics analysis
por: Lu, Jiajie, et al.
Publicado: (2022)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes
por: Wang, Hoau-Yan, et al.
Publicado: (2023)

The Occurrence of Alzheimer’s Disease and Parkinson’s Disease in Individuals With Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Screening Database in Korea
por: Kwon, Mi Jung, et al.
Publicado: (2021)

Mini-review: Angiotensin- converting enzyme 1 (ACE1) and the impact for diseases such as Alzheimer’s disease, sarcopenia, cancer, and COVID-19
por: Bueno, Valquiria, et al.
Publicado: (2023)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

Aberrant Modulations of Neurocognitive Network Dynamics in Migraine Comorbid With Tinnitus
por: Lan, Liping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6im8dt34dhu3d2gr4hauoc56vh